A Vision Without Eye Disease
PulseMedica is developing a platform that is intended to be the first safe, effective, and non-invasive system to screen and treat vitreoretinal disease, starting with symptomatic vitreous opacities (eye floaters).
_edited.png)
Backed by Leading Investors
Millions Worldwide Suffering from Eye Disease
Conditions such as vitreous floaters, age-related macular degeneration (AMD), diabetic retinopathy, and vitreomacular traction affect hundreds of millions of people worldwide.
The Impact of Eye Floaters
52% of adults have floaters, where 5-10% of those impacted experience severe impairments and have no safe and non-invasive treatment options.
-
Vision Impairments
-
Anxiety
-
Stress
-
Depression
-
Reduced Quality of Life
Mild, moderate, and severe impairments from floaters.
The Need For Floater Treatment
There is a significant unmet need for a safe, effective and non-invasive office-based device to screen, diagnose, and treat eye floaters.
Platform Technology
High-Resolution Real Time Imaging
Enhanced Laser Accuracy & Safety
Automated Treatment & Planning
Image Guided Laser Treatment
PulseMedica News and Updates
Latest developments, investments, and breakthroughs in our journey
Meet Our Newest Team Members
We’re excited to introduce new team members helping shape the future of ophthalmology with bold ideas, technical excellence, and a shared commitment to impact.
.jpg)
Ezra Bialowas
Jr. Mechanical Engineer
.jpg)
John Tamkin
Director of Optical Science Research and Development
.jpg)
Shubho Mohajan
Optics Technician